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Background: Transplant recipients are expected to adhere to a lifelong immunosuppressant therapeutic regimen.
However, nonadherence to treatment is an underestimated problem for which no properly validated measurement
tool is available for Portuguese-speaking patients. We aimed to initially validate the Basel Assessment of Adherence
to Immunosuppressive Medications Scale (BAASIS®) to accurately estimate immunosuppressant nonadherence in
Brazilian transplant patients.
Methods: The BAASIS® (English version) was transculturally adapted and its psychometric properties were assessed.
The transcultural adaptation was performed using the Guillemin protocol. Psychometric testing included reliability
(intraobserver and interobserver reproducibility, agreement, Kappa coefficient, and the Cronbach’s alpha) and
validity (content, criterion, and construct validities).
Results: The final version of the transculturally adapted BAASIS® was pretested, and no difficulties in understanding
its content were found. The intraobserver and interobserver reproducibility variances (0.007 and 0.003, respectively),
the Cronbach’s alpha (0.7), Kappa coefficient (0.88) and the agreement (95.2%) suggest accuracy, preciseness and
reliability. For construct validity, exploratory factorial analysis demonstrated unidimensionality of the first three
questions (r = 0.76, r = 0.80, and r = 0.68). For criterion validity, the adapted BAASIS® was correlated with another
self-report instrument, the Measure of Adherence to Treatment, and showed good congruence (r = 0.65).
Conclusions: The BAASIS® has adequate psychometric properties and may be employed in advance to measure
adherence to posttransplant immunosuppressant treatments. This instrument will be the first one validated to use
in this specific transplant population and in the Portuguese language.
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Transplant patients are expected to adhere to a lifelong
therapeutic regimen designed to preserve long-term graft
function and to reduce the risk of complications [1-4].
Adherence is defined by the World Health Organization
as “the extent to which a person’s behavior – taking medi-
cation, following a diet, and/or executing lifestyle changes,
corresponds with agreed recommendations from a health
care provider” [5]. In the setting of transplantation, a recent
consensus conference stated nonadherence (NA) as “devi-
ation from the prescribed medication regimen sufficient to
adversely influence the regimen’s intended effect” [6].
Kidney transplant (KTx) is the most widely performed
transplantation procedure worldwide [7]. In 2010, 16,898
KTx were performed in the United States [7]. In the same
period, 4,630 KTx were also done in Brazil, the second
country in absolute numbers of KTx in the world [8,9].
Some reports have indicated KTx recipients to be the most
nonadherent among transplant patients [3,10]. Indeed, a
recent meta-analysis study revealed that the magnitude of
NA to immunosuppressives in KTx recipients was as
high as 35.6 cases per 100 patients per year, indicating a
prevalence expressive superior than the overall population
of solid organ transplant recipients, which was 22.6 cases
per 100 patients per year [3]. An estimated 15% to 60% of
late acute rejections and 5% to 36% of graft losses were
associated with NA in renal transplant patients [11]. These
data are disturbing given that the odds of graft failure
increases by approximately seven-fold in nonadherent renal
transplant recipients compared with adherent subjects [11].
Given the high number of organ transplantations
performed in Brazil, especially kidney transplants, it is clear
this community needs effective tools to identify patients at
risk of NA. Detection of NA is the first step in identifying
patients at risk who then can be targeted through prevent-
ive and restorative interventions in the transplant popula-
tion [4,12]. Several methods of NA detection in transplant
patients have been suggested in the literature, such as blood
assay, pill count, electronic monitoring, and prescription
refill. These methods can best be used in combination to
maximize the sensitivity and accuracy of adherence meas-
urement, this methodology is called ‘triangulation’ [5,13].
Despite the known limitations, regarding the use of self-
report instruments to measure immunosuppressives NA,
including underreporting and social desirability bias, self-
report instruments are cheap, easy to use, uncomplicated
to score, and applicable as part of a combined diagnosis
strategy. Several self-report methods have been proposed to
measure posttransplant immunosuppressives NA elsewhere
[14]. However, to date, no self-report instrument to assess
NA to immunosuppressive therapy has been validated for
use in Brazilian Portuguese-speaking patients.
Thus, we searched for a self-report method that
we could validate for this purpose and opted for theBasel Assessment of Adherence to Immunosuppressive
Medications Scale (BAASIS®) prompted by a review
published by Dobbels et al. This review favored the
BAASIS® as one of the most optimal self-report instruments
for measuring NA in transplantation [14]. The BAASIS®
assesses relevant dimensions of immunosuppressive drug
use, i.e. taking adherence, timing adherence, drug holidays
and dose reduction in a recording fixed time of the last
four weeks. It is also comparatively shorter than other
self-report methods suggested for assessing NA in
transplant patients [14]. More importantly, the instrument
has already been used in research and clinical practice and
has been chosen by the Transplant360 Task Force to
disseminate, albeit without being fully validated [14-16].
Its validation for transplant populations is in progress in
several projects by the Leuven-Basel Adherence Research
Group (personal communication: Sabina De Geest,
University of Basel, Dec 2012). Moreover, the predictive
validity of the BAASIS® in adult liver transplant recipients
had been recently established (Paolo De Simone, University
of Pisa, manuscript in preparation). The validation
process lacks of standardization and some controversies
about the minimal content of validation studies still
exist. Besides, a primary test of psychometric properties
allows the clinical application and further predictive
analyses [17-19].
Therefore, the aim of this study was to transculturally
adapt and initially validate the BAASIS® to measure




To initially validate the English version of the BAASIS®’
in Brazil, we conducted a single-center cross-sectional
study. Patients were recruited between May 1, 2010 and
December 1, 2010 (Figure 1).
Sample, setting and data collection
We evaluated a convenience sample of 100 KTx patients
who were recruited from the outpatient facility of the
Núcleo Interdisciplinar de Estudos, Pesquisas e Tratamento
em Nefrologia of the Federal University of Juiz de Fora. In
the transcultural adaptation and in reproducibility tests, we
evaluated a subgroup of 21 subjects out of the 100 included
in this study in these patients, measurements were repeated
after seven days [17,18,20] (Figure 1).
Patients were included in the study based on the
following criteria: being at least 18 years old, more
than 1 year after transplantation, and willing to participate
in the study by signing an informed consent form
approved by the local Ethics in Research Committee
of University Hospital of Federal University of Juiz de
Fora (approval number - 0068/2010). The exclusion criteria
Figure 1 Design of the study.
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medication management and illiteracy [10,15].
The instruments BAASIS® and Measure of Adherence to
Treatment (MAT) were administered to included patients
during their regular consultation visit, by transplant trained
nurse interviewers.
Variables and measurements
Demographic and clinical variables were retrieved from
the medical files.
The authors of the BAASIS® provided permission to
translate the copyrighted instrument into Portuguese. It
consists of a four-item questionnaire measuring NA to
immunosuppressives over the past four weeks. It assesses
the crucial dimensions of drug-taking NA (omission of
single doses), drug holidays (omission of successive doses),
timing NA (timing deviations > 2 h) and dose reductions.
Responses are given on a six-point scale: never (0), once
per month (1), every second week (2), every week (3), more
than once per week (4), and every day (5). Patients with any
deviation, namely an answer different from “never” in any
of the four questions, are considered as nonadherent
(Table 1). The interview in the English version of BAASIS ©
starts with a table that assesses the transplant patient’s
medication regimen. The table is filled out by the
health-care professional and the patient together. The
name, dose and dosing frequency and times of each
drug are noted [14,15,21].
Validation procedures
For the BAASIS® initial validation, we followed the
recommended international methods for transculturaladaptation [17,18] and subsequently corroborated the
psychometric properties of the resultant transculturally
translated instrument for adherence to immunosuppressive
medications in KTx patients [22,23].
Transcultural adaptation
Translations The BAASIS® was first individually translated
to Portuguese by two Portuguese-speaking professionals.
The two translations were then compared and synthesized,
producing the first version of the instrument. Next, the first
version was back-translated into English by two other
fluent speaking translators. The researchers synthesized
the new English version and compared the result with
the original so that any inconsistencies could be corrected.
The corrected version was finally approved by the
translators, producing the second Portuguese version
of the questionnaire [17,18].
Expert committee A five-member committee of bilingual
health professionals revised versions 1 (in Portuguese) and
2 (in English) taking into account the semantic, idiomatic,
and conceptual equivalence to identify possible con-
founders in the instrument. We then evaluated the version
generated by the expert committee and implemented their
suggestions to create the third version.
Pretesting The third version was applied to the subgroup
of 21 subjects who, after application, were asked about
their understanding of the instrument content (Figure 1).
Based on their responses, the third version was revised,
producing the fourth and final version of the instrument
in Portuguese (Table 1).
Table 1 The two versions of the BAASIS© scale, original in English and final proposed version
Original version Portuguese version
The Basel Assessment of Adherence with Imunossupressive
Medication Scale (BAASIS)
Escala Basel Paraa Avaliação De Aderência a Medicamentos
Imunossupressores (BAASIS)
1) Do you recall not having taken your immunosuppressive
medications (give name of drugs) some times in the past 4 weeks?
1) Você se lembra de não ter tomado seus remédios imunossupressores
(dê o nome dos remédios) alguma vez nas últimas 4 semanas?
2) Have you skipped several consecutive doses of your
immunosuppressive medications in the past 4 weeks?
2) Você deixou de tomar váriasa doses consecutivas de sua medicação
imunossupressora nas 4 últimas semanas?
3) Do you recall having taken your immunosuppressive
medications with more than 2 hours time difference from the
prescribed dosing time, in the past 4 weeks?
3) Você se lembra de ter tomado seus remédios imunossupressores
com mais de 2 horas de diferença em relação ao horário prescrito,
nas últimas 4 semanas?
4) Have you reduced the prescribed amount of your
immunosuppressive medications during the past 4 weeks?
4) Você tomou uma dose menor do que a dose prescrita
pelo seu médicoa, nas últimas 4 semanas?
( ) yes ( ) no ( ) sim ( ) não
Could you tell me how often this happened: c Você pode me dizer com que freqüência isto aconteceu: c
( ) Never ( ) Nunca
( ) Once a month ( ) Uma vez no mês
( ) Every two weeks ( ) A cada duas semanas
( ) Every week ( ) Toda semana
( ) More than once a week ( ) Mais de uma vez por semana
( ) Every day ( ) Todo dia
a Modifications from the transcultural adaptation are highlighted in italic and underlined.
b © University of Basel, Leuven-Basel Adherence Research Group, Institute of Nursing Science, University of Basel, Belgium, 2005. Permission & conditions to use
the BAASIS® can be obtained from sabina.degeest@unibas.ch.
c The Likert scale should be applied to each of the four items if the answer is yes.
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Reliability Internal consistency was tested by calculating
the Cronbach’s alpha for all the 100 study participants
[23,24]. In those who were submitted to two tests, as
part of test-retest reability, we considered the first result
(Figure 1). Test-retest reliability was assessed using repeated
assessments of the instrument in the subsample of 21
patients. Assessments were performed by the same
observer to test intraobserver reproducibility and by
different observers to test interobserver reproducibility/
interrater reliability over a seven-day period. We then
calculated the variance between the measurements
(interobserver and intraobserver) by applying the Gage’s
variance partition method. Kappa concordance coefficient
was used to evaluate the intraclass correlation of the NA
diagnosis. We also calculated the test-retest categorical
agreement [25].
Validity Content validity was determined during the
transcultural validation of the instrument, using questions
presented to different referees or experts who, in turn, iden-
tified the relevant goals to be measured and analyzed as
representative for each item. The inconsistencies identified
by the committee were all accepted by the investigators,
generating the third version of the instrument [14,22].
Criterion validity was verified by correlating the
transculturally adapted BAASIS® with the MAT scale,
using the Spearman’s correlation coefficient. We chosethe MAT, a medication medication self-report scale for
broad use in medical populations, because it is the only
NA instrument adapted and validated in Portuguese
which approximates our objectives, yet admittedly not
being specifically developed for transplant patients. It
consists of a seven items referring to taking, timing,
and dose reduction, without a fixed recording period.
Any answer different from “never” or “rarely” classifies
a patient as nonadherent [26].
Construct validity, which refers to the ability of each
question to measure a specific aspect of a more general
construct, was verified through Exploratory Factorial
Analysis, using principal components estimates for factor
loadings and the Kaiser-Guttman criterion for dimensional-
ity assessment (eigenvalue ≥ 1) [27].
Statistical procedures
Baseline characteristics were described as mean ± standard
deviation and categorical variables were represented
as frequencies.
As detailed in each specific section above, intraobserver
and interobserver variances by Gage’s variance partition
method, Kappa concordance coefficient, test-retest categor-
ical agreement, Cronbach’s alpha, Spearman’s correlation,
Exploratory Factorial Analysis through principal com-
ponents analysis and the Kaiser-Guttman criterion were
performed using the Statistical Package for the Social
Sciences 15.0 (SPSS Inc., Chicago, IL, USA).
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Sample characteristics
Sixty-five percent of the patients were male, 72% were
white, and the mean age was 45 ± 13.5 years. Regarding
the educational level, 45% completed primary school;
25%, secondary school and 30%, higher education. Most
patients (89%) received their graft from a living donor.
Mean posttransplant time was 72.3 ± 44.4 months. Average
creatinine level was 1.56 ± 0.56 mg/dL. Only 30% lived in
the same city of the transplant center (Table 2). Applying
the final version of the transculturally adapted BAASIS®,
34% of the patients were considered nonadherent.Transcultural adaptation
The process of transcultural adaptation was the first step
for validation of the BAASIS® for the purpose of measuring
the posttransplant patients’ adherence to immunosup-
pressive treatments. The process involved translation,
synthesis, back translation, expert committee evaluation,
and pretesting, as described in the Methods section
[17,18]. The translation, back translation, and synthesis
were uneventful. The expert committee proposed only
three simple modifications concerning the instrument: the
switch in the title (of to for, or “para” in Portuguese) thus
clarifying the purpose of the scale; reintroduction of the
word several (in Portuguese: “várias”) in question 2,
which was omitted during the translating process; and
the introduction of the Portuguese expression “pelo seu
médico” (in English: “by your doctor”) in question 4 to
assure that skipping was arbitrary (Table 1).
None of the 21 participants of the pretest had doubts
of the meaning of or constraints in understanding the
content when answering the third version of the instru-
ment. The Portuguese version of the instrument was thus
originated (Table 1).Table 2 Demographic characteristics
Characteristics %/N
Male gender 65% (65/100)
White race 72% (72/100)
Age (years) 45 ±13.5
Education level
Primary school 45% (45/100)
Secondary school 25% (25/100)
Higher education 30% (30/100)
Mean post-transplant time (months) 72.3 ± 44.4
City of origin
Transplant center 30% (30/100)
Other cities in the same state 43% (43/100)
Other state 27% (26/100)Psychometric properties
To complete the initial validation of the transculturally
adapted BAASIS® instrument, we next assessed its reliability
and the three types of validity (content, criterion, and
construct).
Reliability
The reliability of the instrument, assessed through
intraobserver and interobserver reproducibility, indicated a
very low measurement error of 0.101, which is equivalent
to a measurement variance of 0.010. The interobserver and
intraobserver errors obtained are presented in Table 3.
Cronbach’s alpha was 0.70, indicating moderate internal
consistency. For the Test-Retest subset, Kappa coefficient
was 0.88, the agreement was 95.2%, both indicating almost
perfect agreement.
Validity
Content validity Content validity was undertaken during
the transcultural adaptation stage, using the proposals of
the expert committee, and described above when we
presented the results regarding the transcultural adaptation
stage. The referees suggested modifications only for
questions 2 and 4. There were no suggestions for other
questions. All the inconsistencies were minor and promptly
incorporated into the third version, which was finally
approved by the committee (Table 1).
Criterion validity Criterion validity was determined
through correlations with existing instruments. A
Spearman’s coefficient of 0.65 (p < 0.001) was obtained
when the transculturally adapted BAASIS® was correlated
with the MAT.
Construct validity Applying principal components analysis
and Kaiser-Guttman criterion, we found a scree plot in
which only one factor had an eigenvalue of 1.8 and
accounted for 60% of the total variance, thus, we assumed
only this factor in the subsequent approaches. The explora-
tory factorial analysis demonstrated that questions 1, 2, and
3 of the transculturally adapted instrument had adequate
factorial loads (correlations between the answers to theTable 3 Reliability of the transculturally adapted
BAASIS®, tested by intra and inter-observer
reproducibility measurements
Measurement Variance Standard deviation
Total error 0.010 0.101
Intra-observer 0.007 0.084
Inter-observer 0.003 0.055
a For the inter-observer reproducibility was calculated applying the adapted
version in a sample of 21 subjects by the same observer at baseline and then
by another one 7 days after. For the intra-observer we used the same
procedure without changing the observer at day seven. Differences between
scores obtained are scored as variance.
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close to 1, similar to one another and higher than 0.4. In
contrast, question 4 did not have a good factorial load.
When question 4 was excluded, any important modification
in the factorial loads of the other questions was observed.
So, the question was retained in the BAASIS® Portuguese
version as in the original English version (Table 4).
Discussion
The aim of this study was to translate the BAASIS® in a
culturally sensitive way and to evaluate its psychometric
properties in view of content-, construct- and criterion-
related validities in adult renal transplant recipients. The
BAASIS® was chosen as the most promising self-report
method of assessing patient adherence to immunosuppres-
sive treatment after transplantation in Brazil. While there
are many self-report instruments to assess adherence to
immunosuppression, they have not been validated for use
in Brazil, which is second in the world in terms of absolute
numbers of KTx [9].
Because self-reporting tends to underestimate NA,
selection of the ideal instrument is a crucial step for
the identification of nonadherent patients [14,22]. The
Transplant360 Task Force identified three self-report
NA measurement tools that could be adapted to transplant
clinical practice: the BAASIS®, the Medication Adherence
Self-Report Inventory, and the Brief Antiretroviral
Adherence Index Questionnaire [14]. Indeed, all these
instruments evaluate both the drug taking and the regular-
ity of medication intake and are considered easy to use and
score [14]. Nevertheless, we chose to validate the BAASIS®
because it is concise, it seemed to comprise the relevant
questions, and from the three proposed instruments, it is
the only one already in use for transplant patients in other
countries [15]. Moreover, we recently learned that the
predictive validity of the BAASIS® had been established in
an adult liver transplant population (Dr. Paolo De Simone,
University of Pisa, manuscript in preparation), further
underscoring the value of our choice. We transculturally
adapted and validated the BAASIS® for the assessment of
NA to immunosuppressant treatment in Brazilian KTx
patients, using a previously described protocol [17,18].Table 4 Factorial analysis of the transculturally
adapted BAASIS®
Questions Factorial loads





a The table presents the individual factorial loads of each question of the
transculturally adaptation of BAASIS® for measuring patients’ adherence to
immunosuppressant treatments.Brazil is a continental country. In 2010, its population
reached 190,732,694 despite having many regional
disparities. The Brazilian health system is government
managed and serves majority of the population [9]. Our
study sample reflects many demographic patterns of the
Brazilian KTx population, since it consisted of young
Caucasian individuals, between 40–45 years, most received
living grafts [8,28,29]
The BAASIS® transcultural adaptation was fully ac-
complished by employing an expert committee [17,18].
The five participating professionals analyzed the original
instrument, the translation, the back translation, and
their proposals contributed to the development of the
final version of the instrument. These steps have been
successfully employed for other transcultural adaptations
of other scales [30-32]. As the expert review resulted in
a few changes, we could speculate that the scale is objective
and that the questionnaire could be easily applied to the
transplant population.
The result of the psychometric properties analysis
demonstrated that the transculturally adapted BAASIS®
was a reliable instrument for measuring NA to immuno-
suppressant treatment in the Brazilian KTx patients
investigated in this study. In fact, the intraobserver and
interobserver reproducibility tests revealed little variability.
Moreover the test-retest agreement and intraclass Kappa
correlation were excellent. The results obtained were
similar and therefore reproducible regardless of who
applied the questionnaire or when it was applied, as
indicated by the data. In addition, the Cronbach’s alpha
was 0.70, indicating satisfactory internal consistency
and good measurement performance [22,24]. This level of
internal consistency was also reported for other self-report
instruments for measuring NA to immunosuppressants or
other medications [33,34].
As for content validity, potential misunderstanding
problems were mitigated during the expert committee
evaluation stage and changes were integrated in the
transcultural adaptation step, as previously discussed.
For criterion validity analysis, the instrument to be vali-
dated must be compared with a gold standard [17,18,22]
yet a gold standard for medication adherence measurement
is still lacking [13,35]. Some studies have suggested that
electronic monitoring methods should be adopted as the
standard method as it has superior sensitivity and allows
visualization of medication-taking dynamics [22,36,37].
Unfortunately, due to its considerable cost we were unable
to use this method in our study. Moreover, electronic
monitoring remains an indirect method as ingestion is
not proven. Using immunosuppressives blood levels
are another option, even taking into account its limita-
tions based on individual pharmacokinetic variations.
In our study population, we found a very low frequency
of unacceptable immunosuppressive target levels, 7%
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be inadequate to use for validation. Other methods such as
pill count or use of clinical outcomes are unreliable to
use as a comparison standard. In Brazil, we do not have
a centrally managed database with prescription refills,
limiting the use of this option for validation purposes.
Thus, we correlated the transculturally adapted BAASIS®
with the MAT. Despite the MAT being a general ad-
herence assessment scale and the BAASIS® being an
immunosuppressive-specific instrument, we obtained a
Spearman correlation of 0.65, indicating acceptable
concurrent validity. It must be taken into account that
if the correlation was too high, the transculturally
adapted BAASIS® validation would be immaterial because it
would mean that a validated instrument to measure NA
to immunosuppressant drugs was already established.
Therefore, it seems that the transculturally adapted
BAASIS® presented herein is more appropriate to measure
NA to immunosuppressant treatment than MAT.
We next performed Factorial Exploratory analysis to
assess the construct validity of the transculturally adapted
BAASIS®. Because high factorial loads were obtained
in only one factor, we assumed to be the construct -
adherence, the unidimensionality of the instrument
was demonstrated [25]. Despite question four having the
lowest load, pointing to its less relevant discriminatory
power, its exclusion in a further exploratory analysis
obtained the same unidimensional positive pattern. We
suspected that the universal access to immunosuppressive
medication provided by the public health system in Brazil
could be a possible determinant of these results. We
decided to retain question 4, as in the original version, thus
avoiding the creation of a totally new instrument. However,
the transculturally adapted BAASIS® version should be
further applied in a larger Brazilian patient population
to verify if this pattern of question four will repeat.
One limitation of our study is that we only examined
the transculturally adapted BAASIS® in the context of
assessing NA to immunosuppressant treatment in KTx
patients mostly receiving living grafts. It is reasonable to
think that the instrument initially validated herein will
be also useful to assess NA of patients undergoing other
types of transplants. However, future studies will be
necessary to confirm this supposition. Moreover, the
nonadherence is a complex phenomenon as well its
diagnosis. We have been looking for a gold standard
method for this purpose. Here, we propose to transculturally
adapt and test the psychometric properties, i.e., validation
procedure, of the BAASIS®. In criterion validation we are
supposed to use the gold standard test or as in our case, a
similar instrument. As discussed above we opted to use
the MAT, which have has some limitations but it is
suitable for the process, based on international guide-
lines for instrument development and testing [17,18,22].“However, controversies about the content and methodo-
logical quality of the test validation process remain.
Terwee and colleagues suggested a consistent proposal to
improve the quality of health status questionnaires and to
design validation studies. They enrolled eight psychometric
properties and explicited ranking criteria for each property,
albeit most of the recommendations are directed to
questionnaires with many items. We are glad to report
that applying the proposed guidelines, our validation
process achieved very reasonable scores, achieving a
positive ranking in four and an intermediate ranking in
one, of five applicable items. However, some of the not
graded psychometric properties, as responsiveness and
interpretability, require further longitudinal studies to
complement the initial validation we performed in the
present study [19,38].
The consequences of NA to immunosuppressives are
substantial, not only clinically but also economically,
jeopardizing transplant outcomes [4,5,39,40]. Thus, there
is a critical need to identify, through specific validated
instruments, as those presented in this study, to provide
interventional strategies for nonadherent transplant recip-
ients and further to prevent undesirable adverse events.
Conclusions
The transcultural adaptation of the BAASIS® presented
herein was performed according to international standards.
This transculturally adapted and initially validated in-
strument is the first simple and easy-to-apply self-report
method of detecting immunosuppressant NA in transplant
patients in Brazil and other Portuguese-speaking countries.
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